Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 Consolidation in Limited-stage Small Cell Lung Cancer
CTR20243846Phase 3Terminated
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of risvutatug rezetecan in small cell lung cancer (SCLC), sponsored by Hansoh Pharmaceutical Group. Started Oct 2024; status: terminated.
02
Drugs
risvutatug rezetecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20243846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243846.